Liposome Drug Delivery Market Size & Share, by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B); Technology (Stealth, Non-PEGylated, DepoFoam Liposome Technology); Application (Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, Photodynamic Therapy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4073
  • Published Date: May 01, 2023
  • Report Format: PDF, PPT
  1. Market Definition
    1. Definition
    2. Market Segmentation
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
    3. Secondary Research
  4. Executive Summary – Global Liposome Drug Delivery Market
  5. Market Dynamics
    1. Drivers
    2. Challenges
    3. Trends
    4. Opportunities
  6. Pipeline Analysis
  7. Clinically Marketed Liposome Drugs
  8. Regulatory Scenario Assessment
  9. Analysis on Lipid Nanoparticles
  10. Competitive Landscape
    1. Market Share Analysis, 2021
    2. Company Profiles
      1. Pharmaceutical Formulation Manufacturers
        1. Spectrum Pharmaceuticals, Inc.
        2. Gilead Sciences, Inc.
        3. Celsion Corporation
        4. Ipsen Pharma
        5. Pacira Pharmaceuticals, Inc.
        6. Novartis AG
        7. CordenPharma International
        8. FUJIFILM Toyama Chemical Co., Ltd.
        9. Takeda Pharmaceutical Company Limited
        10. Johnson & Johnson Services, Inc.
        11. Astellas Pharma Inc.
        12. Elan Pharmaceuticals (Perrigo Company plc)
        13. Merrimack Pharmaceuticals, Inc.
        14. Janssen Pharmaceuticals, Inc.
      2. Raw Material Manufacturers
        1. NIPPON FINE CHEMICAL CO., LTD.
        2. Sonic Biochem Extractions Pvt. Ltd.
        3. Croda International Plc
        4. Lipoid GmbH
        5. Hashimoto Electronic Industry Co., LTD
  11. Global Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
        1. Liposomal Doxorubicin, 2021-2031F (USD Million)
        2. Liposomal Paclitaxel, 2021-2031F (USD Million)
        3. Liposomal Amphotericin, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      2. Technology
        1. Stealth Liposome Technology, 2021-2031F (USD Million)
        2. Non-PEGylated Liposome Technology, 2021-2031F (USD Million)
        3. DepoFoam Liposome Technology, 2021-2031F (USD Million)
      3. Application
        1. Fungal Diseases, 2021-2031F (USD Million)
        2. Pain Management, 2021-2031F (USD Million)
        3. Cancer Therapy, 2021-2031F (USD Million)
        4. Viral Vaccines, 2021-2031F (USD Million)
        5. Photodynamic Therapy, 2021-2031F (USD Million)
        6. Others, 2021-2031F (USD Million)
      4. Region
        1. North America, 2021-2031F (USD Million)
        2. Europe, 2021-2031F (USD Million)
        3. Asia Pacific, 2021-2031F (USD Million)
        4. Latin America, 2021-2031F (USD Million)
        5. Middle East & Africa, 2021-2031F (USD Million)
  12. North America Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
        1. Liposomal Doxorubicin, 2021-2031F (USD Million)
        2. Liposomal Paclitaxel, 2021-2031F (USD Million)
        3. Liposomal Amphotericin, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      2. Technology
        1. Stealth Liposome Technology, 2021-2031F (USD Million)
        2. Non-PEGylated Liposome Technology, 2021-2031F (USD Million)
        3. DepoFoam Liposome Technology, 2021-2031F (USD Million)
      3. Application
        1. Fungal Diseases, 2021-2031F (USD Million)
        2. Pain Management, 2021-2031F (USD Million)
        3. Cancer Therapy, 2021-2031F (USD Million)
        4. Viral Vaccines, 2021-2031F (USD Million)
        5. Photodynamic Therapy, 2021-2031F (USD Million)
        6. Others, 2021-2031F (USD Million)
      4. Country
        1. United States, 2021-2031F (USD Million)
        2. Canada, 2021-2031F (USD Million)
  13. Europe Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. Germany, 2021-2031F (USD Million)
        2. United Kingdom, 2021-2031F (USD Million)
        3. France, 2021-2031F (USD Million)
        4. Italy, 2021-2031F (USD Million)
        5. Spain, 2021-2031F (USD Million)
        6. Rest of Europe, 2021-2031F (USD Million)
  14. Asia Pacific Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. China, 2021-2031F (USD Million)
        2. India, 2021-2031F (USD Million)
        3. Japan, 2021-2031F (USD Million)
        4. Australia, 2021-2031F (USD Million)
        5. New Zealand, 2021-2031F (USD Million)
        6. Rest of APAC, 2021-2031F (USD Million)
  15. Latin America Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. Brazil, 2021-2031F (USD Million)
        2. Mexico, 2021-2031F (USD Million)
        3. Rest of LATAM, 2021-2031F (USD Million)
  16. Middle East & Africa Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. GCC, 2021-2031F (USD Million)
        2. South Africa, 2021-2031F (USD Million)
        3. Rest of MEA, 2021-2031F (USD Million)

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Liposome Drug Delivery Market size is anticipated to cross USD 10 billion by the end of 2035, growing at a CAGR of 9% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of liposome drug delivery was around USD 5 billion. The growth of this market can be attributed to the growing demand for effective and efficient therapeutics considering the growing cases of chronic disease all over the world. As a result, drugs are encapsulated into liposomes for effective delivery. According to World Health Organization, 41 million people lose their life owing to chronic disease every year which is equivalent to 74% of death globally.

Increasing advances in liposomal drug delivery methods owing to new investments and ongoing R&D activities, product launches, mergers and acquisitions, and collaborations among major market players, are driving the growth of liposomal drug delivery expected to drive further growth of the market.

Moreover, various government authorities have been seen offering funds and investments for the research and development activities of the liposome drug delivery market. For instance, in 2019, the NIH awarded researchers at the University of Massachusetts Amherst a USD 1.7 million grant to develop new liposome-based vaccine delivery systems.


Liposome Drug Delivery Market
Get more information on this report: Request Free Sample PDF

Liposome Drug Delivery Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Prevalence of Cancer Globally – Liposome drug delivery is widely used in the treatment of cancer owing to its wide range of advantages and properties. In 2020, 10 million people died out of cancer all over the globe and 5 million new cases were recorded. 
  • Growing Significance of Liposomes as a Drug Delivery System - Owing to the importance of liposomes in drug delivery, numerous studies, and clinical trials are ongoing and positive results from these sources are expected to continue to have a positive impact on the growth of the liposome drug delivery market under study. According to the study "Inhaled Liposomal Antimicrobial Delivery in Pulmonary Infections" published in July 2020, the use of inhaled liposomal antimicrobial therapy in pulmonary infections resulted in the antimicrobial agent targeting the infective organisms at the site of infection, thereby increasing the intracellular antibiotic concentration. It reduces drug toxicity and improves tolerability. 
  • Increased Use of Quality by Design (QbD) Over Traditional Methods- As a consequence of the popularity of rational-based methods like QbD over empirical and simulation-based techniques, procedures have been upgraded. In contrast to traditional techniques that rely on trial and error, QbD is based on a fact-based rational strategy that allows for superior decision-making. The popularity and application of the QbD approach are expected to propel market growth.

Challenges

  • High Cost of Development of the Drug Delivery System – Liposome drug delivery can be expensive and can limit access for patients who cannot afford it. This can be a particularly big challenge in developing countries with limited healthcare budgets. 
  • Limited Clinical Data
  • Competition from Drug Delivery Technologies

Liposome Drug Delivery Market: Key Insights

Base Year

2022

Forecast Year

2023 – 2035

CAGR

~9%

Base Year Market Size (2022)

~USD 5 billion

Forecast Year Market Size (2035)

~USD 10 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Liposome Drug Delivery Segmentation

Application (Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, Photodynamic Therapy)

The cancer therapy segment in the liposome drug delivery market is anticipated to hold the largest revenue share of 41% by the end of 2035. This can be attributed to the high prevalence of cancer and the growing demand for advanced therapeutics. As cancer is one of the diseases which attracts more attention from the R&D owing to its high prevalence and seriousness, this segment is anticipated to grow in the upcoming times. According to a report, there were approximately 19.3 million new cancer diagnoses worldwide in 2020, with breast cancer being the most common cancer, followed by lung cancer.

Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B)

The liposomal doxorubicin segment is anticipated to hold 38% share of the global liposome drug delivery market by the end of 2035. This segment includes liposomes that are used to deliver the chemotherapy drug doxorubicin. Liposomal doxorubicin is effective in treating certain types of cancer, such as ovarian and breast cancer which is further expected to contribute to the growth of the segment over the coming decades.

Our in-depth analysis of the global market includes the following segments:

          Product

  • Liposomal Doxorubicin
  • Liposomal Paclitaxel
  • Liposomal Amphotericin B

         Technology

  • Stealth
  • Non-PEGylated
  • DepoFoam Liposome Technology

         Application

  • Fungal Diseases
  • Pain Management
  • Cancer Therapy
  • Viral Vaccines
  • Photodynamic Therapy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Liposome Drug Delivery Industry - Regional Synopsis

North American Market Forecast

The liposome drug delivery market in North America is projected to garner the largest revenue of 45% by the end of 2035. The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems. According to the statistics by the National Cancer Institute (NCI), in the year 2020, the new cases of cancer that were expected to be diagnosed in the United States were about 1806590 cases. The statistics also stated that during the same year, 606520 people were expected to die as a result of the disease.

Europe Market Forecast

On the other hand, the liposome drug delivery market in Europe is projected to garner the second-largest revenue of 31% by the end of 2035. The market in Germany is projected to garner the second-largest revenue by the end of 2035 in Europe. The growing incidence of chronic illnesses including cancer and cardiovascular disease is driving the market. The rising demand for personalized medicine and the need for improved drug efficacy and safety are driving market growth.  The market for liposome delivery in Europe is highly regulated with stringent safety and efficacy guidelines. Companies operating in the market must comply with these regulations to obtain approval for their products.

Research Nester
Liposome Drug Delivery Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Liposome Drug Delivery Landscape

top-features-companies
    • Spectrum Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Gilead Sciences, Inc.
    • Celsion Corporation
    • Ipsen Pharma
    • Pacira Pharmaceuticals, Inc.
    • Novartis AG
    • CordenPharma International
    • FUJIFILM Toyama Chemical Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson Services, Inc.

In-the-news

In The News

  • Endo Ventures Limited (EVL), a subsidiary of Endo International plc, agreed with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company, will commercialize his TLC product, TLC599, which is under investigation. TLC599 is an injectable compound in Phase III development for the treatment of knee osteoarthritis knee pain.
  • Pfizer and Acuitas Therapeutics entered into a Development and Options Agreement. This gives Pfizer the option to license Aquinas lipid nanoparticle (LNP) technology non-exclusively for up to 10 vaccine targets or therapeutics development.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4073
  • Published Date: May 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising prevalence of cancer globally, and the increasing application of liposomes as a drug delivery system are some of the major factors anticipated to drive market growth.

The market size of capsaicin is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2035.

North America is estimated to create notable growth opportunities for market growth over the forecast period.

The major players in the market are Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., and Others.

The liposomal doxorubicin segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Liposome Drug Delivery Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying